SI1879901T1 - Pirolobenzodiazepini - Google Patents

Pirolobenzodiazepini

Info

Publication number
SI1879901T1
SI1879901T1 SI200630604T SI200630604T SI1879901T1 SI 1879901 T1 SI1879901 T1 SI 1879901T1 SI 200630604 T SI200630604 T SI 200630604T SI 200630604 T SI200630604 T SI 200630604T SI 1879901 T1 SI1879901 T1 SI 1879901T1
Authority
SI
Slovenia
Prior art keywords
me3sn
nhr
halo
nitro
optionally substituted
Prior art date
Application number
SI200630604T
Other languages
English (en)
Inventor
Stephen J Gregson
Zhizhi Chen
Philip Wilson Howard
Original Assignee
Spirogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0508084A external-priority patent/GB0508084D0/en
Priority claimed from GB0522746A external-priority patent/GB0522746D0/en
Application filed by Spirogen Ltd filed Critical Spirogen Ltd
Publication of SI1879901T1 publication Critical patent/SI1879901T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200630604T 2005-04-21 2006-04-21 Pirolobenzodiazepini SI1879901T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0508084A GB0508084D0 (en) 2005-04-21 2005-04-21 Pyrrolobenzodiazepines
GB0522746A GB0522746D0 (en) 2005-11-07 2005-11-07 Pyrrolobenzodiazepines
EP06726846A EP1879901B1 (en) 2005-04-21 2006-04-21 Pyrrolobenzodiazepines

Publications (1)

Publication Number Publication Date
SI1879901T1 true SI1879901T1 (sl) 2010-04-30

Family

ID=36589321

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630604T SI1879901T1 (sl) 2005-04-21 2006-04-21 Pirolobenzodiazepini

Country Status (19)

Country Link
US (2) US7612062B2 (sl)
EP (1) EP1879901B1 (sl)
JP (1) JP5061096B2 (sl)
KR (1) KR101396095B1 (sl)
AT (1) ATE452898T1 (sl)
AU (1) AU2006238686B2 (sl)
BR (1) BRPI0610284A8 (sl)
CA (1) CA2604805C (sl)
CY (1) CY1109911T1 (sl)
DE (1) DE602006011300D1 (sl)
DK (1) DK1879901T3 (sl)
ES (1) ES2338696T3 (sl)
GB (1) GB2439881C (sl)
MX (1) MX2007013039A (sl)
NZ (1) NZ563136A (sl)
PL (1) PL1879901T3 (sl)
PT (1) PT1879901E (sl)
SI (1) SI1879901T1 (sl)
WO (1) WO2006111759A1 (sl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5079103U (sl) * 1973-11-24 1975-07-09
GB9818730D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
EP2270010B1 (en) * 2004-03-01 2012-01-25 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404574D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
EP1723152B1 (en) * 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
DE602006011300D1 (de) * 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
ATE427949T1 (de) * 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
KR100952137B1 (ko) * 2008-04-18 2010-04-09 실리콘 디스플레이 (주) 입체 영상 디스플레이 장치 및 그 제조방법
WO2010008208A2 (ko) 2008-07-17 2010-01-21 주식회사 파버나인코리아 유기 발광 다이오드 입체영상 표시장치
GB0813432D0 (en) * 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0819095D0 (en) * 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
AU2011239525B2 (en) * 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines used to treat proliferative diseases
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
RS59253B1 (sr) 2011-05-08 2019-10-31 Legochem Biosciences Inc Konjugati aktivnog agensa proteina i postupak za njihovo dobijanje
AU2012311505B2 (en) 2011-09-20 2016-09-29 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
US9526798B2 (en) * 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EA036202B1 (ru) * 2011-10-14 2020-10-14 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
JP6117801B2 (ja) 2011-10-14 2017-04-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン
KR101891859B1 (ko) 2011-10-14 2018-08-24 메디뮨 리미티드 피롤로벤조디아제핀
US9321774B2 (en) 2012-04-30 2016-04-26 Medimmune Limited Pyrrolobenzodiazepines
AU2013255613B2 (en) 2012-04-30 2017-06-22 Medimmune Limited Pyrrolobenzodiazepines
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906248B1 (en) 2012-10-12 2018-12-05 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EA032986B1 (ru) 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびその結合体
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びそのコンジュゲート
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
TW202214691A (zh) 2014-03-21 2022-04-16 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
US10160812B2 (en) 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
JP6863888B2 (ja) 2014-10-01 2021-04-21 メディミューン,エルエルシー ポリペプチドをコンジュゲートさせる方法
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
WO2016115201A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
BR112017014599A2 (pt) 2015-01-14 2018-01-16 Bristol-Myers Squibb Company dímeros de benzodiazepina, conjugados dos mesmos, e métodos de preparação e uso
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
KR20180019592A (ko) 2015-06-23 2018-02-26 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 벤조디아제핀 이량체, 그의 접합체, 제조법 및 용도
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US9873708B2 (en) 2015-07-21 2018-01-23 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
US11414477B2 (en) 2016-01-27 2022-08-16 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CA3027103A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214335A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
EP3468599A2 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN110049780A (zh) 2016-10-10 2019-07-23 塞勒兰特治疗公司 异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
NZ752394A (en) 2016-11-14 2021-07-30 Hangzhou Dac Biotech Co Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
GB201619490D0 (en) * 2016-11-17 2017-01-04 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TWI755450B (zh) 2016-11-23 2022-02-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗-prlr抗體藥物軛合物(adc)及其用途
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
CN111164208B (zh) 2017-09-29 2023-08-04 第一三共株式会社 抗体-吡咯并苯并二氮杂卓衍生物偶联物
ES2920123T3 (es) 2017-11-14 2022-08-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3801630A1 (en) 2018-05-25 2021-04-14 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3866856A1 (en) 2018-10-19 2021-08-25 MedImmune Limited Pyrrolobenzodiazepine conjugates
US20210316006A1 (en) 2018-10-19 2021-10-14 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL297818A (en) 2018-12-21 2023-01-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND THEIR USES
SG11202108900WA (en) 2019-03-15 2021-09-29 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ,インク. 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
WO2021195469A1 (en) 2020-03-27 2021-09-30 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5569587A (en) * 1978-11-17 1980-05-26 Meiji Seika Kaisha Ltd Novel antibiotic neothramycin derivative and its preparation
JPS5615289A (en) * 1979-07-17 1981-02-14 Green Cross Corp:The Novel benzodiazepinnbased compound 3
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質dc−81およびその製造法
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
FR2696176B1 (fr) * 1992-09-28 1994-11-10 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
GB9818730D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818732D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
DK1109812T3 (da) * 1998-08-27 2005-09-05 Spirogen Ltd Pyrrolobenzodiazepiner
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6909006B1 (en) * 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
US6660856B2 (en) * 2002-03-08 2003-12-09 Kaohsiung Medical University Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
GB0416511D0 (en) * 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
AU2004284075A1 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
EP2270010B1 (en) * 2004-03-01 2012-01-25 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404574D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
EP1723152B1 (en) 2004-03-09 2015-02-11 Spirogen Sàrl Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
DE602006011300D1 (de) * 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
ATE427949T1 (de) * 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung

Also Published As

Publication number Publication date
GB2439881A (en) 2008-01-09
KR101396095B1 (ko) 2014-05-15
CY1109911T1 (el) 2014-09-10
GB2439881B (en) 2009-04-08
JP5061096B2 (ja) 2012-10-31
NZ563136A (en) 2009-11-27
EP1879901B1 (en) 2009-12-23
US20100113425A1 (en) 2010-05-06
JP2008536905A (ja) 2008-09-11
ES2338696T3 (es) 2010-05-11
DK1879901T3 (da) 2010-05-03
PT1879901E (pt) 2010-03-29
US20080167293A1 (en) 2008-07-10
MX2007013039A (es) 2008-03-13
CA2604805A1 (en) 2006-10-26
GB2439881C (en) 2011-08-10
US8633185B2 (en) 2014-01-21
GB0720721D0 (en) 2007-12-05
CA2604805C (en) 2014-05-27
AU2006238686A1 (en) 2006-10-26
BRPI0610284A8 (pt) 2017-05-09
US7612062B2 (en) 2009-11-03
WO2006111759A1 (en) 2006-10-26
PL1879901T3 (pl) 2010-06-30
ATE452898T1 (de) 2010-01-15
BRPI0610284A2 (pt) 2010-06-08
KR20080004618A (ko) 2008-01-09
AU2006238686B2 (en) 2011-10-06
EP1879901A1 (en) 2008-01-23
DE602006011300D1 (de) 2010-02-04

Similar Documents

Publication Publication Date Title
GB2439881C (en) Pyrrolobenzodiazepines
MX2019012467A (es) Conjugados de pirrolobenzodiazepina.
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
WO2005110423A3 (en) Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias
EA201692215A1 (ru) Пирролбензодиазепины и конъюгаты направленного действия
MX341523B (es) Pirrolobenzodiazepinas.
TR200101507T2 (tr) Geniş antibakteriyel spektrumu olan imidazo[4,5-b] piridinyummetil-içerikli sefem bileşimleri
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
WO2007106192A3 (en) Inhibitors of iap
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
HK1090647A1 (en) Oxazolidinone-quinolone hybrid antibiotics
WO2008002596A3 (en) Adenosine a2a receptor antagonists
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
BR0213140A (pt) Fungicidas de pirazol-pirimidina
TW200740781A (en) Novel compounds
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
TW200716597A (en) Novel piperidine-substituted indoles
MY136824A (en) Substituted benzoxazinones and uses thereof
MXPA04006041A (es) Antivirales de piridoquinoxalina.
CY1113733T1 (el) Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
MY138826A (en) 2,7-substituted indoles
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
MXPA04005157A (es) Procedimientos para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.